P Martinez-Martin1,2, F G Radicati3, C Rodriguez Blazquez1,2, J Wetmore1, N Kovacs4,5, K Ray Chaudhuri6,7, F Stocchi3. 1. National Center of Epidemiology, Carlos III Institute of Health, Madrid, Spain. 2. Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain. 3. University and Institute for Research and Medical Care IRCCS San Raffaele, Roma, Italy. 4. Department of Neurology, Medical School, University of Pecs, Pecs, Hungary. 5. MTA-PTE Clinical MRI Research Group, Pecs, Hungary. 6. National Parkinson Foundation International Centre of Excellence, King's College Hospital, London, UK. 7. Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Abstract
BACKGROUND AND PURPOSE: A composite instrument able to rapidly and reliably assess the most relevant motor and non-motor afflictions suffered by Parkinson's disease (PD) patients in a real world clinic setting is an unmet need. The recently validated PD Composite Scale (PDCS) was designed to fulfil this gap as a quick, comprehensive PD assessment. The objective of this study was extensive evaluation of the PDCS's clinimetric properties using a large international sample. METHODS: This was a cross-sectional study in which the PDCS, the Movement Disorder Society Unified Parkinson's Disease Rating Scale and the Clinical Impression of Severity Index for PD were applied. Basic clinimetric attributes of the PDCS were analysed. RESULTS: In total, 776 PD patients were included. The PDCS total score showed negligible floor and ceiling effects. Three factors (54.5% of the variance) were identified: factor 1 included motor impairment, fluctuations and disability; factor 2, non-motor symptoms; and factor 3, tremor and complications of therapy. Cronbach's alpha was from 0.66 to 0.79. Inter-rater reliability showed weighted kappa values from 0.79 to 0.98 for items and intraclass correlation coefficient values from 0.95 (Disability) to 0.99 (Motor and total score). The Bland-Altmann method, however, showed irregular concordance. PDCS standard error of measurement and convergent validity with equivalent constructs of other measures were satisfactory (≥0.70). PDCS scores significantly differed by Hoehn and Yahr stage. CONCLUSION: Overall, in line with previous findings, the PDCS is a feasible, acceptable, valid, reliable and precise instrument for quickly and comprehensively assessing PD patients.
BACKGROUND AND PURPOSE: A composite instrument able to rapidly and reliably assess the most relevant motor and non-motor afflictions suffered by Parkinson's disease (PD) patients in a real world clinic setting is an unmet need. The recently validated PD Composite Scale (PDCS) was designed to fulfil this gap as a quick, comprehensive PD assessment. The objective of this study was extensive evaluation of the PDCS's clinimetric properties using a large international sample. METHODS: This was a cross-sectional study in which the PDCS, the Movement Disorder Society Unified Parkinson's Disease Rating Scale and the Clinical Impression of Severity Index for PD were applied. Basic clinimetric attributes of the PDCS were analysed. RESULTS: In total, 776 PDpatients were included. The PDCS total score showed negligible floor and ceiling effects. Three factors (54.5% of the variance) were identified: factor 1 included motor impairment, fluctuations and disability; factor 2, non-motor symptoms; and factor 3, tremor and complications of therapy. Cronbach's alpha was from 0.66 to 0.79. Inter-rater reliability showed weighted kappa values from 0.79 to 0.98 for items and intraclass correlation coefficient values from 0.95 (Disability) to 0.99 (Motor and total score). The Bland-Altmann method, however, showed irregular concordance. PDCS standard error of measurement and convergent validity with equivalent constructs of other measures were satisfactory (≥0.70). PDCS scores significantly differed by Hoehn and Yahr stage. CONCLUSION: Overall, in line with previous findings, the PDCS is a feasible, acceptable, valid, reliable and precise instrument for quickly and comprehensively assessing PDpatients.
Authors: Irene A Malaty; Pablo Martinez-Martin; K Ray Chaudhuri; Per Odin; Matej Skorvanek; Joohi Jimenez-Shahed; Michael J Soileau; Susanna Lindvall; Josefa Domingos; Sarah Jones; Ali Alobaidi; Yash J Jalundhwala; Prasanna L Kandukuri; Koray Onuk; Lars Bergmann; Samira Femia; Michelle Y Lee; Jack Wright; Angelo Antonini Journal: BMC Neurol Date: 2022-01-24 Impact factor: 2.474
Authors: Soo Jeong; Eun-Jae Lee; Yong-Hwan Kim; Jin Cheol Woo; On-Wha Ryu; Miseon Kwon; Sun U Kwon; Jong S Kim; Dong-Wha Kang Journal: J Stroke Date: 2022-01-31 Impact factor: 6.967
Authors: Roberta Balestrino; Carlos Alberto Hurtado-Gonzalez; Fabrizio Stocchi; Fabiana Giada Radicati; K Ray Chaudhuri; Carmen Rodriguez-Blazquez; Pablo Martinez-Martin Journal: NPJ Parkinsons Dis Date: 2019-11-27